B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels

B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels

Objectives. To correlate the kinetics of B-cell repopulation with relapse after B-cell depletion therapy in SLE patients and address whether variation in relapse rate, B-cell numbers and phenotype are related to anti-dsDNA antibody levels.

Bibliographic Details
Main Authors: Lazarus, Mark N., Turner-Stokes, Tabitha, Chavele, Konstantia-Maria, Isenberg, David A., Ehrenstein, Michael R.
Format: Online
Language:English
Published: Oxford University Press 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380246/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380246/

Similar Items